COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
25/06/2018
Expected closing of $25.5 million in capital to be used to accelerate EyePoint’s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches anticipated [...]
Unum Therapeutics Joins Russell 3000® Index
25/06/2018
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq:UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal [...]
Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
25/06/2018
Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 25 June 2018 [...]
BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
25/06/2018
China Chairman of NCCN Guidelines for Neutropenia Management, Dr. Yuankai Shi, Presented Positive Clinical Data Update on BeyondSpring’s Lead Asset, Plinabulin NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring [...]
Easton Pharmaceuticals Strengthens its Board of Directors While Enhancing Existing Businesses and Moves Towards New Sectors and Industries
25/06/2018
TORONTO, ON, June 25, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC:EAPH) is pleased to announce the appointment of Mr. Panagis (“Panos”) Alivizatos, to its Board of Directors to enhance existing businesses [...]
International Stem Cell Corporation Publishes Advanced Stem Cell Therapy Methodology in Stem Cells and Development Journal
25/06/2018
CARLSBAD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company [...]
REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
25/06/2018
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of [...]
Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors
25/06/2018
DURHAM, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition to her board [...]
Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares
25/06/2018
HAMILTON, Bermuda, June 25, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing [...]
Prodigy Health announces the launch of Prodigy Connect Real Time Inventory Management for High Value Specialty Pharmaceuticals
25/06/2018
AUSTIN, Texas, June 25, 2018 (GLOBE NEWSWIRE) -- Prodigy Health, a national specialty drug distributor that is leveraging innovative technology solutions for managing specialty pharmaceuticals in the hospital supply [...]
Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries
25/06/2018
VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed [...]
PledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote®
25/06/2018
PledPharma (publ) announces today that internationally leading experts will join a newly established Scientific Advisory Board to support the continued global clinical development of Aladote ® – a drug candidate being [...]
Solon Eiendom ASA : Primary insider notification
25/06/2018
(Oslo, Norway, June 22, 2018) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 25,000 shares in Solon Eiendom ASA at a price of NOK 29.31 per share. [...]
Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US
25/06/2018
Today PledPharma (publ) announces that the company has received a positive conclusion of the safety evaluation from the Data Safety Monitoring Board for the Aladote proof of principle study in patients with paracetamol [...]
CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer
25/06/2018
CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer Collaboration with world-leading prostate cancer researcher, Professor Johann de Bono of The Institute of Cancer Research, [...]
Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018
25/06/2018
Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018 Amsterdam, The Netherlands, June 25, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS ), a clinical [...]
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
25/06/2018
DUBLIN - June 24, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 million [...]
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
24/06/2018
Conference call on Monday, June 25th at 2:30 pm CET/8:30 am EDT Focuses development efforts on solid tumor indications Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic [...]
ERYTECH confirme l’orientation stratégique d’eryaspase dans les tumeurs solides et interrompt ses développements dans la Leucémie Aiguë Lymphoblastique (LAL)
24/06/2018
Conférence téléphonique lundi 25 juin à 14h30 (heure de Paris) Concentration du développement sur les indications de tumeurs solides Confirmation du lancement d’un essai randomisé de Phase 2 dans le traitement de [...]

Pages